Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 16Gastrointestinal 8Thoracic 7Breast 7Genitourinary 6Head & Neck 5Sarcoma 3Dermatologic 3Other solid neoplasm 2CNS 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Brain Neoplasms 33Glioblastoma 32Melanoma 21Glioma 19Neuroblastoma 7Carcinoma, Renal Cell 6Carcinoma, Non-Small-Cell Lung 6Astrocytoma 6Ependymoma 5Colorectal Neoplasms 5Central Nervous System Neoplasms 5Recurrence 4Ovarian Neoplasms 4Medulloblastoma 4Lymphoma 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Rhabdomyosarcoma 3Pancreatic Neoplasms 3Osteosarcoma 3Meningioma 3Lung Neoplasms 3Gliosarcoma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

X-Rays 2Trastuzumab 2Specimen Handling 2Nivolumab 2Irinotecan 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1spartalizumab 1sargramostim 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1montelukast 1larotrectinib 1ipatasertib 1erdafitinib 1entinostat 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Nivolumab × CNS × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡